ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1902

What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout?

Nicola Dalbeth1, Meaghan House2, Anne Horne2, Keith J. Petrie3, Fiona M. McQueen4 and William Taylor5, 1Medicine, University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Auckland, Auckland, New Zealand, 4Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, 5University of Otago, Wellington, New Zealand

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Gout and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Long term serum urate (SU) lowering to a target of <6mg/dL is recommended for effective gout management.  However, many studies have reported low achievement of SU targets.  The aim of this study was to examine the clinical and psychological factors associated with SU targets in patients with gout. 

Methods: Patients with gout for <10 years were recruited from primary and secondary care settings.  SU target was defined as SU concentration <6mg/dL at the time of the study visit. Both clinical and psychological factors associated with SU target were analysed.  The relationship between SU target and measures of gout activity including flare frequency in the preceding three months was also analysed. 

Results: Of the 273 patients enrolled into the study, 89 (32.6%) had SU concentration <6mg/dL.  Urate-lowering therapy (ULT) use was strongly associated with SU target (p<0.001).  In those patients prescribed ULT (n=181), allopurinol dose, patient confidence to keep SU under control, female sex, and ethnicity were independently associated with SU target (Table).  Other patient psychological factors and health-related behaviours, including adherence scores, were not independently associated with SU target in those taking ULT.  Creatinine clearance, diuretic use, age, and body mass index were not associated with SU target.  Patients at SU target reported lower gout flare frequency, compared with those not at target (p=0.03).

Conclusion: ULT prescription and dosing are key modifiable factors associated with achieving SU target.  These data support interventions focusing on improved use of ULT to optimise outcomes in patients with gout. 

Table. Forward stepwise logistic regression analysis of factors associated with SU target in those taking ULT. Model included all factors with p<0.15 between groups in univariate analysis.

Variable

OR

95% CI

p

Model

Female sex

4.34

1.65-11.44

0.003

Adjusted R2=0.35,

p<0.001

Māori or Pacific ethnicity

0.19

0.07-0.52

0.001

Allopurinol dose (per every 100mg/day)

2.22

1.43-3.44

<0.001

Confidence to keep serum urate under control (per every point on 0-10 Likert scale)

1.025

1.007-1.044

0.006

Excluded from model: adherence score, secondary care treatment, age, confidence to have blood tests at recommended frequency, confidence to take gout medications regularly, Brief Illness Perception Questionnaire (BIPQ) treatment control score, BIPQ understanding score.

 


Disclosure:

N. Dalbeth,
None;

M. House,
None;

A. Horne,
None;

K. J. Petrie,
None;

F. M. McQueen,
None;

W. Taylor,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-factors-are-associated-with-target-serum-urate-concentrations-in-patients-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology